SAN DIEGO, Feb. 19, 2020 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth
quarter and full-year 2019 financial results and provide a
corporate update on Wednesday, February 26,
2020, after the close of the U.S. financial markets. The
Company will host a conference call and live webcast to discuss the
results with the investment community the same day at 4:30 PM ET.
Conference Call & Webcast Information
When:
Wednesday, February 26, 2020, at
4:30 PM ET
Dial-in: (877) 643-7155 (United
States) or (914) 495-8552 (International)
Conference ID: 8286947
Please join the conference call at least 10 minutes early to
register. You can access the live webcast under the investor
relations section of Arena's website. A replay of the conference
call will be archived for 30 days after the call.
About Arena Pharmaceuticals
Arena
Pharmaceuticals is uniquely positioned to develop
best-in-disease medicines with optimized efficacy and safety for
patients globally. Our drive to deliver a robust pipeline of novel,
transformational medicines is grounded in two decades of world
class G-protein-coupled receptor (GPCR) discovery research.
It is the breadth and depth of our portfolio, prioritization of
drug development to meet unmet patient needs, strong financial
health and growing, bold-thinking world-class team that gives Arena
the ingredients and passion to build a sustainable, vibrant
next-generation pharmaceutical company.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Arena's upcoming conference call and live webcast
with the investment community and Arena's position, drive,
portfolio, prioritization, financial position, team, and building
of the company. For such statements, Arena claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include those disclosed in Arena's
filings with the Securities and Exchange Commission. These
forward-looking statements represent Arena's judgment as of the
time of this release. Arena disclaims any intent or obligation to
update these forward-looking statements, other than as may be
required under applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
IR@arenapharm.com
858-453-7200
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-release-fourth-quarter--full-year-2019-financial-results-and-provide-corporate-update-on-february-26-301007890.html
SOURCE Arena Pharmaceuticals, Inc.